Thota Kanishka Rao, Amity University Kolkata
Cancer is one of the most dangerous diseases causing the death of millions globally. 1 out of every 6 deaths, around 6,000 people each day. There is no single test that can precisely analyze malignancy. The total evaluation of a patient for the most part requires a thorough history and actual assessment alongside diagnostic testing.
Nowadays, researchers are using CRISPR technology to track the lineage of individual cancer cells as they proliferate and metastasize in real-time.
When cancer is bound to one spot in the body, specialists can commonly treat it with surgery or other treatments. Much of the mortality related to disease, however, is because of its propensity to metastasize, conveying seeds of itself that flourish all through the body. The exact moment of metastasis is cursory, lost in the large numbers of divisions that occur in a tumor.
Tracking cells utilizing CRISPR yielded some intriguing outcomes. For a certain something, singular tumor cells were very different from one another than the researchers anticipated. The cells the researchers utilized were from established human lung cancer in the lungs cell line called A549. They were thought to be homologous, but to their surprise, they observed we saw dramatic differences in the propensity of different tumors to metastasize — even in the same mouse. Some had a very small number of metastatic events, while the others were rapidly dividing.
About this heterogeneity, the researchers implanted two clones of the same cells in two different mice. As the cells proliferated, the researchers observed that the descendants metastasized at a remarkably similar rate, while on the other hand, the offspring of different cells from the same cell line evolved different metastatic potentials as the cell line was maintained over many generations.
The researchers wondered about the type of genes responsible for this variability between cancer cells from the same cell line. Various genes stuck out, even though it was not clear whether they were driving the metastasis or just a result of it. One of them, the gene that codes for the protein Keratin 17, is considerably more unequivocally expressed in low metastatic tumors than in highly metastatic tumors.
This CRISPR technique additionally permitted the researchers to track with more detail where the metastasizing cells went in the body, and when. Mapping tumor movement in this manner permitted the researchers to make a couple of intriguing observable facts about the mechanics of metastasis. A few clones seeded in a textbook way, going from the left lung, where they began, to distinct territories of the body. Others seeded all the more sporadically, moving first to different tissues before metastasizing again from that point.
In the future, the researchers yearn to move past just observing the cells and start to foresee their conduct.
Also read:THE BRAIN’S REWARD SYSTEM: NEUROBIOLOGY OF DRUG ADDICTION
Source:
“Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts” by Jeffrey J. Quinn, Matthew G. Jones, Ross A. Okimoto, Shigeki Nanjo, Michelle M. Chan, Nir Yosef, Trever G. Bivona and Jonathan S. Weissman, 21 January 2021, Science. DOI: http://10.1126/science.abc1944
One thought on “CRISPR To Track Cancer In The Cells”